Literature DB >> 9386987

Mutants of basic fibroblast growth factor identify different cellular response programs.

W P Leenders1, V W van Hinsbergh, S T van Genesen, J G Schoenmakers, E J van Zoelen, N H Lubsen.   

Abstract

Mutations, expected to affect the intracellular routing, i.e. additional nuclear localization sequences (NLS; the natural 23 kDa isoform and a 17D27R mutant) and/or a deletion of amino acids 26-29 (23 delta 26-29 and 17 delta 26-29), were introduced in basic fibroblast growth factor (bFGF). The mutants were assayed for their mitotic activity and their capacity to induce a tissue-specific response in human umbilical vein endothelial cells [HUVECs; induction of urokinase plasminogen activator receptor (u-PAR)], or in rat lens epithelial cells (fibre cell differentiation). In HUVECs, the 17D27R mutant had wild type activity, the 23 kDa and the delta 26-29 proteins were impaired in the induction of both mitosis and u-PAR. The delta 26-29 proteins, but not the 23 kDa protein or 17D27R mutant, were also impaired in receptor binding in that they bound only to a subset of receptors. The concentration of 17 kDa bFGF required for half maximal u-PAR response was 30 fold higher than for the half maximal 3H-thymidine incorporation. Addition of an NLS to bFGF strongly inhibited the induction of fibre cell differentiation, though it had little effect on the stimulation of DNA synthesis. The 17 delta 26-29 kDa mutant had wild type differentiation activity but was a poor mitogen for lens epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9386987     DOI: 10.3109/08977199709021521

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  1 in total

1.  A versatile salt-based method to immobilize glycosaminoglycans and create growth factor gradients.

Authors:  Danique J Hof; Elly M M Versteeg; Chris H A van de Lest; Willeke F Daamen; Toin H van Kuppevelt
Journal:  Glycoconj J       Date:  2019-05-04       Impact factor: 2.916

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.